Strong growth for its orphan, rheumatology, and primary care drugs translated to a great first quarter for Horizon.
News & Analysis: Horizon Pharma
HZNP earnings call for the period ending March 31, 2019.
These three momentum stocks have a lot more upside.
Earnings season is approaching its end, but some stocks are still seeing big gains.
Horizon's experimental thyroid eye disease treatment hit the mark in a late-stage trial today.
HZNP earnings call for the period ending December 31, 2018.
These three mid-cap companies could deliver big wins for long-term investors.
Horizon's shares got a boost from the company's outstanding third-quarter earnings report yesterday.
Investors looking for value stocks should start with these leaders of unloved industries.
The specialty pharma company announced record results for the second quarter of 2018.